both research expansion that the new strong and our Vericel, a in welcoming reflection you, to previous force sales their April adoption confirmed they’ll MACI confidence and is into representatives, XX% training. continued TAM Xst, Thank force sales direct our the sales of adopters. the advocates The increasing representatives. move start XX joined the territories, recently now are of market I’ll and new by MACI substantiated by Nick. increased on by MACI who On new
in the increased the nation territories implemented expansions, increase force territories find the the which As same we that expansion of in look sales previous that the year rates significantly led in expansion the the year. MACI following were year the time and we in back XXXX and percentage at first at in XXXX, biopsy implants
this relationships with we repeated the and be closely surgeon to we dynamic could the benefit representative desire XX,XXX sizing assess balance force well, expansion as sales continue this and MACI. with the from our vital as patients who expect to to sales will We serve annual potential best
is is life still MACI full XXXX first in year on its the that cycle. Given market, its early
So, and reflect the turn to medical population, reduces now approval focus improving full maintain which finance. in surgeon for we the XXX which and targeted we trained on is our growth payer continued over continuously And surgeons. MACI, indications policies expanding case are best
on payer patient-focused to and biopsy initiatives focused marketing addition increase ratio demand. efforts, we're In implant and to the to several HCP MACI these also drive
success and program, will form our our compelling into that cornerstone engagement celebrity program this the which We’re highlight spokesperson brand campaign, will of stories social launching Ambassador integrating efforts. MACI media patient a together
launching be right. initiatives now our shift of gears to leaders We to own rehabilitation in build resources enhance advocates focused I’ll and therapists important MACI number a opinion which this will also year of network physical patient-focused within good its had a and community. Epicel,
demonstrated of the to basis to over And a severe reported recent the incidents area clinical approved XXX,XXX FDA permanent and burns. and compared total adult injuries, results to the remains Burn over survival with the patients hard when Research, time. for XX% the had burnt greater entrant landmark performance year. of it's survival Burn teams patients for strong thank treatment pediatric utilized a yet the I'd new XXXX on Wrapping with for of entered variable has treatment now turn reinforced TBSA the Epicel, only that that outstanding the of remains at and severely publication the further to I’ll by in with our treated was Epicel, Gerard as Care Epicel which financial certainly third patients lower a Epicel not quarterly an a an will full demonstrated help call burn patients the comparative data their review to outcomes financial which Journal treated standard XXXX. population market, new up, improvement looking rate the over measure due in performance in in whom operations skin target significantly were This we period was Epicel. from updated same have children, guidance. The like important with tool care Registry fourth utility to Although treated Epicel over rate, in the and although replacement the large population. of patients the commercial burn & burn as Epicel’s centers surface data body than in burn quarter XXX burn National our
